Abstract: The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).

Abstract: The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.

Abstract: The present invention relates to a process for the preparation of iodinated phenols, —in particular, it relates to a process including the electrochemical iodination of 3,5-disubstituted phenols of formula (1) to the corresponding 3,5-disubstituted-2, 4,6-triiodophenols of formula (2), which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves. Furthermore, the present invention includes the electrochemical iodination of 3, 5- disubstituted anilines of formula (6) to the corresponding 3,5-disubstituted-2,4,6-triiodoanilins of formula (7).

Abstract: The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme.

Abstract: The invention relates to a method for producing polysaccharide esters or polysaccharide mixed esters, in which a polysaccharide or a modified polysaccharide is converted with at least one esterification reagent and at least one halogenide component, an imidazole compound which is generated in situ being used as catalyst.

Abstract: Compounds useful for the treatment of giardiasis are described.

Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.

Abstract: A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having a rheology similar to that of synovial liquid and always with an elevated resistance to degradation due to a synergistic action between the hyaluronic acid and the polyols.

Abstract: The invention relates to a complex made of ?-cyclodextrin and a halogenated ether, characterized by a content of the halogenated ether of at least 3 wt % of the total weight of the complex.

Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.

Abstract: Stable needle shaped crystals of natamycin having a mean length of between 0.1 and 20 ?m.

Abstract: Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the phthaloyl group, a fatty acid may be added on the terminal glucosamine unit, forming a lipochitooligosaccharide. The processes can be adapted for use on a commercial scale.

Abstract: The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus Capsicum, and in particular may be isolated from sweet bell peppers (C. annuum). Pharmaceutically-acceptable salts, enantiomers, diasteriomers, racemic mixtures, enantomerically-enriched mixtures, solvates, and prodrugs of such compounds are also disclosed. Pharmaceutical compositions and methods of using such compounds, including pharmaceutical compositions and methods of using such compounds in combination with one or more active ingredients, are also disclosed.

Abstract: The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside.

Abstract: Provided is hydroxyalkyl methylcellulose which can be dissolved at room temperature of 20 to 30° C. and has high thermoreversible gel strength during thermoreversible gelation. More specifically, provided is water-soluble hydroxyalkyl methylcellulose having a molar substitution of hydroxyalkoxyl groups of 0.05 to 0.1 and a substitution degree of methoxyl groups of 1.6 to 1.9, wherein the hydroxyalkoxyl groups are classified into substituted hydroxyalkoxyl groups having hydroxyl groups of hydroxyalkoxyl groups substituted further with methoxyl groups and unsubstituted hydroxyalkoxyl groups having hydroxyl groups of hydroxyalkoxyl groups not further substituted; and a ratio (A/B) of a molar fraction (A) of the substituted hydroxyalkoxyl groups to a molar fraction (B) of unsubstituted hydroxyalkoxyl groups is 0.4 or greater.

Abstract: A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:

Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.

Abstract: The invention relates to the use of a compound comprising D-mannoheptulose and/or perseitol for producing a drug for treating and/or preventing diseases related to the modification of an innate and/or acquired immunity by increasing the production of antimicrobial peptides, preferably hBD-2 without inducing inflammatory reactions, irritation or intolerance. Said compound can also comprise a peptidic avocado extract an/or a peptidic lupin extract.

Abstract: Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain substantially pure steviol glycoside compositions comprising approximately 95% or greater steviol glycosides and approximately 75% or greater rebaudioside A with a single crystallization step.

Abstract: The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.